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883-6 Acute Myocardial infarction Study of Adenosine 
(AMISTAD II) 
Allan Ross, Ray Gibbons, Robed A, Kloner, Victor J. Marder, Gragg W. Stone, R Wayne 
Alexander, George Washington University Medical Center, Washington, DisL of 
Columbia, Emory University School of Medicine, Atlanta, Georgia. 
Background: A previous study of adenosine infusion in the treatment of acute myocardie~ 
infarction (AMISTAD I) suggested clinical efficacy. The potential role of adenosine as an 
effective therapeutic agent in the treatment of MI has remained in question. To approach 
this problem, a randomized, double blind, placebo controlled, multicenter trial (AMISTAD 
II) was performed. 
Methods: The study involved 248 clinical sites in 13 countries (2,118 patients random- 
ized) participating in the main trial, with 62 sites in 4 countries (263 patients) participating 
in a substudy utilizing Tc-99m sestamibi single photon emission computed tomography 
(SPECT) imaging at 120 to 216 hours post randomization for assessment of final infarct 
size. 
Eligible patients with evolving anterolateral myocardial infarction were randomized to 
treatment with a 3 hour infusion of adenosine of 60 mcg/kg/min, 70 mcg/kg/min, or pla- 
cebo. Patients received study medication within +15 minutes of initiation of thrombolytic 
therapy or within 15 minutes prior to pdmary percutaneous mechanical reperfusion. 
Patients were followed untU hospital discharge and throughout a 6 month period after 
randomization for assessment of primary and secondary endpoints, clinical events, and 
safety. 
The primary efficacy endpoint was time from randomization to the first occurrence of con- 
gestive heart failure (CHF) in-hospital (>24 hours post randomization), or the first rehos- 
pitalization for CHF during follow-up, or death from any cause. The secondary efficacy 
endpoints were all cause mortality, cardiovascular mortality, and myocardial infarct size 
measured by SPECT imaging, Safety endpoints were assessed by following adverse 
events occurring during the first 48 hours following randomization, and changes in blood 
pressure and heart rate during the study drug infusion. Clinical events reported include 
all cause hospitalization, reinfarction, stroke, and revascularization (thrombolysis, perou- 
taneous mechanical reperfusion, or coronary artery bypass graft surgery (CABG)). 
Results: The enrollment and follow-up have been completed for all patients. Results will 
be available in fourth quarter 2001 and will be discussed. 
886-2 Excessive Tumour Necrosis Factor Activation Post- 
Infarction Contributes to the Early Susceptibility to 
Myocardial Rupture: Evidence From TNF-/- Transgenic 
Knockout Models 
Mei Sun, Fayez Dawood, Wen-Hu Wen, Josef Panninger, Peter Liu, Heart & Stroke/ 
Richard Lewar Centre of Excellence, U of Toronto, Toronto, Ontario, Canada, Toronto 
Genera/Hospital UHN, Toronto, Ontario, Canada. 
BACKGROUND: We have previously demonstrated that tumour necrosis factor (TNF) is 
expressed in high levels in the post-infarction (MI) myocardium, and may orchestrate 
inflammation and matrix repair. However, excessive TNF activation may contribute to 
early myocardial rupture. 
METHODS: To examine the role of TNF levels in matrix healing post MI, we generated 
MI in C57/BL wild type mice that are rupture prone, and compared them to TNF-/- 
homozygous knockout animals in the same background. The animals were randomized 
to LAD ligation or sham operation, and the mortality, ventricolar morphology, inflamma- 
tory cell infiltrate and local collagen formation were compared. 
RESULTS: The wild type C57BL mice had higher of mortality post MI at 21 days (67% in 
TNF+/+ and 43% in TNF-/-, p<0.05), with the early deaths between days 3-7 were mainly 
attributed to myocardial rupture. Pathology revealed extensive inflammatory cell infiltrate 
and poor collagen formation in the wild type animals, associated with very high levels of 
local TNF production. Knockout TNF-/- littermates in contrast had lower incidence of rup- 
ture, and more attenuated inflammatory infiltrate, but more late ventricular dilatation in 
the survivors. Apoptosis detected by TUNEL and DNA ligase techniques showed exten- 
sive signals in the infarct, border as well as normal remote zone in wild type animals, but 
significantly attenuated in the TNF-/- models. MMP9 activation, associated with wound 
repair, was extensive in the TNF-/- mice, but was confined only to the central infarct zone 
in the wild type animals prone to rupture. 
CONCLUSIONS: We conclude that host predisposition towards high TNF production in 
the post MI myocardium lends susceptibility to infarct rupture. The ability to decrease 
excessive TNF production leads to improved scar formation, less myocardial rupture and 
lower modality, and may represent an interesting approach in high risk rupture prone sit- 
uations post-myocardial infarction. 
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886-1 Patients With Coronary Artery Disease Treated With 
Statina Have Decreased Heat Production From Culprit 
Lesions 
Christodoulos Stafanadis. Konstantinos Toutouzas, Eleftherios Tsiamis, Menolis 
Vavouranakis, Ioannis Kallikazaros, Sophia Vaina, Christina Chrysochoou, Dimos 
Panagiotakos, Christos Pitsevos, Pavlos Toutouzas, Hippokration Hospital, Athens, 
Greece. 
Background: It has been previously shown, that a local inflammatory process is 
involved in atherosclerotic plaques, resulting in increased heat production of the culpdt 
lesions. Also, it has been shown that statins may play an important role in plaque stabili- 
zaflon, due to an additional anti-inflammatory effect. The purpose of the present study 
was to evaluate the effect of statins on atherosclerotic plaque stabilization by measuring 
the temperature of atherosclerotic plaques. Methods: The study population included 86 
patients (pts), 26 pts with stable angina (SA), 36 pts with unstable angina (UA), and 24 
pts with acute myocardial infarction (AMI). All pts underwent diagnostic catheterization. 
Under stalin treatment were 46 pts (14 pts with SA, 18 pts with UA and 14 pts with AMI) 
for a period of over a month, and 40 pts were not receiving statins (12 pts with SA, 18 pts 
with UA and 10 pts with AMI). Aspirin was administered in 65 pts. Total cholesterol and 
low-density cholesterol were measured in all pts. During the diagnostic catheterization, 
we measured the temperature difference (TD) between the atherosclerotic plaque and 
the healthy vessel wall with a thermography catheter previously validated (Medispes 
S.W.A.G.zug-Switzerlend). Results: TD was progressively increased form pts with SA to 
UA and AMI (0.32 ± 0.1 vs 0.41 ± 0.28 vs 0.68 ± 0.41°C, p < 0.02). When we categorized 
the study population into pts receiving statins and pts not treated with statins, TD was 
lower in the treated group (0.30 ± 0.31 vs 0.57 ± 0.40°C, p < 0.01). Moreover, treated pts 
within each clinical syndrome had lower TD compared to untreated pts (SA: 0.23 ± 0.16 
vs. 0.42 ± 0.24°C, p < 0.02, UA: 0.29 ± 0.25 vs. 0.45 ± 0.26°C, p < 0.02 and AMI: 0.56 ± 
0.34 vs. 0.62 ± 0.51°C, p < 0.01). Multivariate analysis showed that treatment with statins 
was an independent factor in the assessment of temperature variation, adjusted for age, 
hypercholesterolemia, hypertension, smoking, aspirin intake, and clinical syndrome. 
Conclusions: Treatment with statins results in less heat production from the culprit 
lesion, indicating stabilization of the culprit atherosclerotic plaque. 
886-3 Sphingosine Contributes to Tumor Necrosis Factor-a- 
Mediated Contractile Dysfunction in Response to 
Coronary Mlcroembollzation 
Matthias Thielmann. Claus Martin, Hilmar Ddrge, Sergej Belosjorow, Uwe Schwanke, 
Arne KrOger, Anita van de Sand, Ina Konietzka, Rainer Schulz, Gerd Heusch, 
Department of Pathophysio/ogy, University of Essen, Essen, Germany. 
Backround: Coronary microembolization results in patchy microinfarction, leukocyte 
infiltration, and increased myocardial tumor necrosis factor-c~ (TNF-(~) levels and finally 
progressive myocardial contractile dysfunction. The negative inotropic effects of TNF-c~ 
in vitro are in part mediated by sphingosine. We therefore examined the effect of the 
ceramidase inhibitor N-oleoylethanolamine (NOE) on myocardial TNF-(~ content (WEHI 
cytolytic bell assay), sphingosine content (HPLC) and contractile function (sonomicrome- 
try) after coronary microembolization in vivo. 
Methods: In enflurane-anesthetized ogs, coronary microembolization was induced by 
infusion of 3,000 microspheres (42 ~m diameter) per ml/min of inflow into the left circum- 
flex coronary artery. Eleven dogs served as controls, whereas six dogs received NOE (74 
p.g/kg IV over 15 min before coronary microembolization, followed by 2.4 I~g/kg/min for 8 
hours). 
Results: In both, controls and dogs receiving NOE, TNF-(x content was increased in the 
microembolized postedor wall (controls: 2039 ± 1122 (mean+ SD), NOE: 1510 ± 457 U/g 
wet weight) over that in the anterior wall (controls: 1070 ± 543, NOE: 973 ± 435 U/g wet 
weight). The sphingosine content was increased in the posterior wall in controls (406 ± 
147 posterior VS. 244 ± 67 pmol/g wet weight anterior wall). While NOE did not change 
the sphingosine content in the anterior wail it completely prevented the increase in the 
postedor wall (241 ± 61 posterior vs. 200 ± 52 pmol/g wet weight antedor wall). Systemic 
hemodynamics and anterior systolic wall thickening remained unchanged for 8 hours 
after microembolization. Posterior systolic wall thickening in controls decreased progres- 
sively (20.6 ± 4.9 % at baseline to 4.1 ± 3.7 % at 8 hours after microembolization). In 
contrast, NOE prevented such decrease in contractile function (19.5 ± 5.7 % at baseline 
vs. 16.4 ± 6.3 % at 8 hours after coronary microembolization). 
Conclusion: Sphingosine acts downstream of TNF-~ and is causally involved in the cor- 
onary microembolizeflon-induced progressive contractile dysfunction. 
11:15 a.m. 
886-4 Ant ibod ies  to Human Heat Shock Protein 60 Pred ic t  
Risk of  Myocard ia l  In farct ion  or  Death In Women 
Jianhui ZhIJ, Joseph B. Muhtsstein, Javier F'. Nieto, Amy Wasserman, Benjamin D. 
Home, Jeffrey L. Anderson, Stephen E. Epstein, Washington Hospital Center, 
Washington, Dist. of Columbia, LDS Hospital Salt Lake Ci~ Utah. 
Background: We previously demonstrated that antibodies to human heat shock protein 
(HSP) 60 are associated with both the presence and severity of coronary artery disease 
(CAD). In the present prospective study, we examined the relation of human HsP60 anti- 
bodies to risk of myocardial infarction (MI) or death among patients with significant CAD 
by angiography. Methods: Blood samples from 880 patients (77% men, mean age 65 
years)were tested for HSP60 IgG antibodies (ELISA). Mean follow-up was 3 years. 
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Results: IgG antibodies to human HSP60 were detected in 67% of the patients. HSP60 
antibodies were not associated with the risk of the development of MI or death (P>0.05). 
However, there were sex-based differences in the relation between the presence of 
HSP60 antibodies and the development of MI or death. In women, 130 of 204 (64%) had 
HSP60 antibodies. The risk of MI or death was increased in seroposltive compared to 
seronegative patients (relative hazards 2.2, 95% CI 1.10-4.47). This association per- 
sisted after adjustment for traditional risk factors, number of diseased vessels and clinical 
presentation. The adjusted relative hazard (with 95% CI) for MI or death was 2.1 (1.03- 
4.29). No association between HSP60 antibodies and infection or inflammation was 
found. In contrast, in men, 460 of 676 (68%) were HSP60 antibody seroposltive. There 
was no positive association between HSP60 seropositivity and MI or death (P>0.05). 
Conclusion: Although the mechanisms by which HSP60 antibodies predisposes to MI or 
death in CAD patients are unclear, this is the first study demonstrating a significant asso- 
ciation between human HSP60 antibodies and the risk of the development of MI or 
death. That this association occurs only in women is compatible with the conclusion that 
the mechanisms contributing to atherogenesis are different between men and women, 
and that in women, autoimmune mechanisms contribute to the development of athero- 
sclerosis, with one antigenic target being HSP60. 
11:30 a.m. 
886-5 Prognostic Value of Markers of Myocardial Damage and 
Inflammation in Low to Intermediate Risk Chest Pain 
Patients 
Radha Bhotasingh, Jan H. Cornel, Otto Kamp, Alphons Wiodhausen, Marc van der Zee, 
Jan van Straalen, Gerard T. Sanders, Robbert J. de Winter, Academic Medica/Center 
Amsterdam, Amsterdam, The Netherlands. 
Background: Systemic activation of inflammation has been associated with poor prog- 
nosis in patients with chest pain. We prospectively studied the prognostic value of car- 
diac troponin T (cTnT) (marker of myocardial damage) and C-reactive protein (CRP), 
erythrocyte sedimentation rate (ESR) and white blood cell count (WBC) (markers of 
inflammation) in low to intermediate risk chest pain patients. 
Methods: Patients presenting at the cardiac emergency room with chest pain of -< 6 
hours duration and a normal or non-diagnostic electrocardiogram were eligible. Signifi- 
cant unstable coronary artery disease was ruled out using standard protocol and CK-MB 
and patients were subsequently discharged. CRP, ESR and WBC (admission) and serial 
cTnT (admission and 12 hours after symptom onset) were measured. CRP and cTnT 
results were blinded. All patients were followed up at 6 months. Cardiac events were car- 
diac death, acute myocardial infarction (AMI), and unstable angina (UA) requiring hospi- 
tal admission. 
Results: In 401 patients, cTnT and CRP results were available; 16 had a cardiac event: 
cardiac death (3), AMI (3) and UA (10). Results are displayed in the table. 
Cardiao event rate (%) Odds Ratio (95%CI) 
cTnT<0.06 ng/mL (Normal) 12/373 (3.2) 
cTnT_>O.06 ng/mL 4/28 (14.3) 5.01 (1.50-16.72) 0.019 
CRP<3.0 ng/mL (Normal) 4/247 (1.6) 
CRP>3.0 mg/L 12/154 (7.8) 5.13 (1.63-16.22) 0.003 
ESR<_ 13 mm/hr (Normal) 5/266 (1.9) 
ESR> 13 mm/hr 11/127 (8.7) 4.95 (1.68-14.57) 0.004 
Normal cTnT, Normal CRP 4/235 (1.7) 
Normal cTnT, Abnormal CRP 8/138 (5.8) 3.55 (1.05-12.03) 0.037 
Conclusion: In univariate analysis, serial cTnT, CRP, and ESR (but not WBC) each had 
significant prognostic value in low to intermediate risk chest pain patients in the emer- 
gency room. In patients with normal serial cTnT, CRP was able to distinguish low risk 
patients from not low-risk patients 
11:45 a.m, 
886-6 The Prognostic Significance of Myoglobin in the 
Emergency Department in Patients With Chest Pain 
~ames M¢Cord, Michael P. Hudson, Richard M. Nowak, Michael C. Tomlanovich, Glenn 
Tokarski, Gordon Jacobsen, W. Douglas Weaver, Henry Ford Hospital, Detroit, Michigan. 
BACKGROUND: The utility of troponin in risk stratification ofpatients that present o the 
emergency department(ED) with chest pain is well-established, but the prognostic signlt. 
icance of myoglobin(myo) in this patient population is less certain. We investigated 
whether the early measurement ofmyo contdbutad additional prognostic information i  a 
targe urban ED. 
METHODS: During 1999, 762 consecutive patients were evaluated in the ED for possi- 
ble myocardial infarction(MI). Patients with ST-segment elevation MI were excluded. 
Blood samples were collected at 0 hour, 90 minutes, and 9 hours for measurements of 
myo, CK-MB, and cardiac troponin I(cTnl) with a point-of-care device(Triage Cardiac, 
Biosite). 
RESULTS: At 30 days there were 121 patients with adverse events (AE)(43 deaths, 73 
MIs, and 46 revascularization procedures). Receiver operator curve analysis determined 
an optimum myo cut-point of 225 ng/ml to predict an AE. After multivariable adjustment 
for clinical factors, elevated serial myo values at presentation and 90 minutes were pre- 
dictive of an AE(table). Also, after adjusting for cTnl and CK-MB values at presentation 
and 90 minutes myo added additional prognostic information(odds ratio 4.03(2.15- 
7.54);p<O.000f)). 
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CONCLUSION: The early measurement of myo at presentation and 90 minutes adds 
additional prognostic information to clinical findings and CK-MB and cTnl values in ED 
patients with suspected MI. 
Odds Ratio of Elevated Myo for Adverse Event(gs% Confidence Interval) 
0 Hour 90 Minutes 9 Hours 
Multivariable Adjustment for 4.24(2.34-7.69) 10.68(4.32-26.43) 0.88 (0.37-2.08) 
Clinical Factors p<0.0001 p<0.0001 p=0.78 
